Kornimate/medical-research-clean huggingface dataset:
treatment of hamstring muscle in patients with low-back pain

Conditions: Low Back Pain

Summary: this study evaluates the treatment of hamstrings in the management of patients with mechanical low back pain of non-specific origin. half of the participants will received the application of a dry needle technique in the most hyperalgesic areas of the muscle, while the other half will received the same technique in areas not hyperalgesic.

shortening of the hamstrings could be related to low back pain.therefore, the treatment of these muscles may improve pain. the dry needling technique seems to improve the extensibility of the muscles. this technique seems to be more effective when is applied in the most hyperalgesic areas related to the participant's pain. in order to demonstrate this hypothesis, the investigators will check if the dry needling technique produces the same effects when is applied in other areas of those same muscles

Eligibility criteria:
inclusion criteria: * nonspecific chronic low back pain lasting ≥ 3 months. * age between 18 and 65 years. * history of non-specific lumbar pain not irradiated to lower extremities of at least 1 year of evolution. * those subjects who have not received a physiotherapy session in the last 6 months. exclusion criteria: * specific low back pain (infection, tumor, inflammation, canal stenosis, spondylolisthesis, hernia or disc prolapse, structural deformity, rheumatic disease, radicular pain, cauda equina, previous history of spinal surgery). * fibromyalgia. * treatment with corticosteroids or oral medications in the last 6 months. * history of spinal surgery. * contraindications typical of deep dry puncture (needle phobia, coagulation or psychological disorders, varicose regions, cysts, wounds, metal or latex allergy, lymphedema, hypothyroidism, diabetes). * those subjects with a value of 0º in the active knee extension (ear) test. * pregnancy

Keywords: pain back hamstrings
clinical and radiomic model of covid-19

Conditions: Coronavirus; Machine Learning

Summary: to develop and validate a machine-learning model based on clinical, laboratory, and radiological characteristics alone or combination of covid-19 patients to facilitate risk assessment before and after symptoms and triage (home, hospitalization inward or icu).

in december 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (sars-cov-2; earlier named as 2019-ncov), emerged in wuhan, china. the diseases caused by sars-cov-2 is covid-19. as of march 8, 2020, more than 100 000 covid-19 patients have been reported globally (more than 80 000 cases in china, more than 20 000 in other countries), and 3 600 patients (3 100 in china, 500 outside of china) have died. the outbreak of covid-19 constitutes a public health emergency of international concern. among covid-19 patients, around 80% are mild (non-severe) illness patients, who usually heal within two weeks. however, another 20% of patients may aggravate into a severe or critical illness which results in a longer hospital stay, and the mortality rate for such patients is 13.4%. therefore, inchoate identification of the high-risk severe patients is extremely important for patient management and medical resource allocation. general quarantine and symptomatic treatment can be used for most non-severe patients, while a higher level of care and green channel to the intensive care unit (icu) are helpful for severe patients. previous studies have summarized the clinical and radiological characteristics of severe covid-19 patients, while which factors are important predictors is still unclear. machine learning is a branch of artificial intelligence that enables us to learn knowledge and potential laws from the given data and to build a model for solving problems as human needs. in recent years, machine learning has been developed as a novel tool to analyze large amounts of data from medical records or images. previous modeling studies focused on forecasting the potential international spread of covid-19. therefore, our purpose is to develop and validate a machine-learning model based on clinical, laboratory, and radiological characteristics alone or combination of covid-19 patients in the early stage without severe illness from multiple centers for the prediction of severe (or critical) illness in the following hospitalization to facilitate risk assessment before and after symptoms and triage (home, hospitalization inward or icu).

Eligibility criteria:
inclusion criteria: * confirmed covid-19 patients by high-throughput sequencing or real-time reverse-transcriptase polymerase-chain-reaction (rt-pcr) assay for nasal and pharyngeal swab specimens. exclusion criteria: 1. patients with severe illness when admitted; 2. time interval \> 2 days between the admission and examinations; 3. absent data or delayed results
a comparison of recall rates between conventional 2d mammography and 2d plus 3d (tomosynthesis) mammography in a screening population

Conditions: Breast Cancer

Summary: the primary aim of this study is to measure, document and compare recall rates of two-dimensional plus three dimensional (2d plus 3d) (tomosynthesis) mammography to that of 2d mammography in a screening population. this study will compare recall rates for both non-cancer and cancer cases.


Eligibility criteria:
inclusion criteria: * subject is female of any race and ethnicity * the subject is asymptomatic and presents for routine screening mammography and chooses to have a combination 2d + 3d mammogram as her standard of care. exclusion criteria: * patient chooses standard 2d mammography over a combination 2d + 3d mammogram

Keywords: breast cancer screening tomosynthesis ffdm
biomechanical assessment and biofeedback-training system for handwriting

Conditions: Writing Learning Disability

Summary: the purpose of this study is to investigate the real-time kinetics of handwriting regarding the design of the utensil and fine motor performances from biomechanical perspectives. it includes three parts. the first part is an observational study design and the specific aim of the first part of the study is to establish a novel kinetic assessment system incorporated with force acquisition pens (faps) designed with different barrel sizes and shapes for handwriting. the thorough calibration, examination of reliability and validity will be presented in this study. the second part is also an observational study design and the specific aim of the second part of the study is to investigate the handwriting mechanisms using the kinetic assessment system incorporated with the motion capture system with children who have writing difficulties. the third part is an interventional study design and the aim of this final part is to integrate the kinetic assessment system and the intervention concept to establish a biomechanical assessment and biofeedback-training system for handwriting (babsh). comparison of the intervention effect of the babsh and traditional training for the children with handwriting difficulties will also be carried out in this part.


Eligibility criteria:
inclusion criteria: 1. able to use pen to write 2. children volunteers must study in elementary schools exclusion criteria: - handwriting problems are related to muscular, skeletal, nerve and brain damage or disease.

Keywords: handwriting kinetics kinematics handwriting difficulty
study of standard chop versus biweekly chop in aggressive non-hodgkin's lymphoma (jcog9809)

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, bi-chop in comparison to standard chop for advanced intermediate or high grade non-hodgkin's lymphoma (nhl).

the purpose of jcog9809 was to determine whether treatment results of aggressive nhl could be improved by shortening intervals of chop chemotherapy with the prophylactic use of g-csf. the primary endpoint was progression free survival (pfs), and the planned accrual was 450. until december, 2002, 323 patients with advanced aggressive nhl were randomized to standard chop arm (chop x 8, every three weeks) and biweekly chop arm (chop x 8, every two weeks).

Eligibility criteria:
inclusion criteria: * intermediate- or high-grade non-hodgkin's lymphoma, excluding cutaneous t-cell lymphoma (ctcl), adult t-cell leukemia-lymphoma (atl) and t-cell lymphoblastic lymphoma (t-lbl) (working formulation) * ann arbor stage: ii, iii, iv * no prior chemotherapy or radiotherapy * age: 15 to 69 * performance status (ps): 0, 1, 2 * wbc \>= 3,000 /mm3, anc \>= 1,200 /mm3, platelet \>= 75,000 /mm3 * got/gpt \<= 5 x normal upper limit, t-bil \<= 2.0 mg/dl * creatinine \<= 2.0 mg/dl * normal ecg, ejection fraction \>= 50% * pao2 \>= 65 mmhg * written informed consent exclusion criteria: * uncontrollable diabetes mellitus * severe complication (infection, heart failure, renal failure, liver failure, etc) * anamnesis of heart disease * acute or chronic hepatitis, liver cirrhosis and portal hypertension * synchronous or metachronous malignancy * severe pulmonary dysfunction * central nervous system (cns) invasion * hiv positive * hepatitis b surface antigen (hbs-ag) positive * hepatitis c virus antibody (hcv-ab) positive

Keywords: non-hodgkin's lymphoma intermediate-grade lymphoma high-grade lymphoma chop protocol granulocyte-colony stimulating factor
lenalidomide in combination with r-gemox in first-line treatment of elderly diffuse large b cell lymphoma

Conditions: Diffuse Large B Cell Lymphoma

Summary: the purpose of this study is to investigate efficacy and safety of lenalidomide in combination with r-gemox as first-line treatment of elderly patients with diffuse large b cell lymphoma.

gemcitabine and oxaliplatin(gemox) shows effective activity in patients with relapsed diffuse large-cell lymphoma and other solid tumors. the purpose of this study is to investigate efficacy and safety of lenalidomide in combination with r-gemox as first-line treatment of elderly patients with diffuse large b cell lymphoma.

Eligibility criteria:
inclusion criteria: 1. the histopathologic diagnosis was dlbcl (except primary mediastinal large b cell lymphoma, primary central lymphoma, hiv related lymphoma). 2. age older than 70 years or older than 60 years with eastern cooperative oncology group(ecog) performance status(ps) ≥ 2; 3. expected survival ≥ 12 weeks; 4. at least a measurable or evaluable disease at the time of enrolment (diameter ≥1.5cm); 5. understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements; 6. all patients must agree to take effective contraceptive measures during the trial measures exclusion criteria: 1. active hepatitis b or hepatitis c virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to hiv infected persons 2. patients known to have varicella or herpes zoster virus infection 3. previous exposure to any anti-tumor therapy 4. poor hepatic and/or renal function, unless these abnormalities were related to the lymphoma 5. poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/l or platelet count less than 75×109/l, unless caused by bone marrow infiltration 6. history of deep vein thrombosis (dvt) or pulmonary embolism (pe) within past 12 months 7. new york heart association class iii or iv cardiac failure; or ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome#acute heart failure#severe ventricular arrhythmia 8. central nervous system (cns) or meningeal involvement 9. known sensitivity or allergy to investigational product 10. major surgery within three weeks 11. patients receiving organ transplantation 12. patients with secondary tumour, excluding cured (5 years without relapse) in situ non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer, gastrointestinal intramucous carcinoma and breast cancer 13. presence of grade iii nervous toxicity within past two weeks 14. active and severe infectious diseases 15. any potential drug abuse, medical, psychological or social conditions which may disturb this investigation and assessment 16. in any conditions which investigator considered ineligible for this study. 17. histologic transformation

Keywords: r-gemox lenalidomide
phase ii study of hmpl-004 in patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to evaluate the safety and efficacy of hmpl-004 in patients with active mild to moderate ulcerative colitis (uc), compared with placebo.

this is a double-blind, randomized, placebo-controlled phase ii study conducted in north america (u.s. and canada) and europe (romania and ukraine) in patients with mild to moderate ulcerative colitis. treatment consisted of one of 2 doses of hmpl-004 (1200 mg daily or 1800 mg daily, administered in 3 divided doses) or matching placebo. assessment of treatment effect is based on the mayo score. subjects eligible for the study will include those ≥18 years of age with mild to moderate ulcerative colitis, having a mayo score of 4 to 10, with activity confirmed by endoscopy within 2 weeks prior to study entry, and having a mayo endoscopy score ≥1. subjects who are using concomitant mesalamine could enter the study. the randomization will be stratified by mesalamine use or non-use.

Eligibility criteria:
inclusion criteria: * have active confirmed mild to moderate ulcerative colitis exclusion criteria: * diagnosed with crohn's disease or
the exploration of an active training tool to reduce weight bias among students pursuing a healthcare-related degree

Conditions: Obesity Bias

Summary: an open-label parallel rct will be conducted among 220 students pursuing a health-related degree at ariel university. the intervention tool will be based on the constructive social learning model and will include a short lecture on obesity, scenarios simulating a meeting between health professionals and patients with obesity that will be presented by professional role-players and include varying degrees of weight bias, stigma and discrimination, and an open discourse with a patient with obesity. the tool's development will be carried out throughout recommended steps including a comprehensive literature review, preparation of a preliminary draft of the plan, evaluation of the planned intervention tool in terms of content validity, and a pilot testing of the tool among n=15 students from the target population. the control group will receive a short-written document on obesity. this study will utilize an embedded mixed-method approach. at baseline, one- and six- weeks post-intervention both groups will be asked to fill an anonymous online survey which will include demographics, weight and body perception, knowledge about obesity, the anti-fat attitudes questionnaire, the short-form of fat-phobia scale, and the weight-implicit association-test. moreover, in-depth interviews will be conducted among 15 participants from each group.


Eligibility criteria:
inclusion criteria: * undergraduate students pursuing a healthcare-related degree including nutrition science, health systems management, communication disorders, physiotherapy, occupational therapy, and nursing at ariel university * age ≥18 years * willingness to participate in the study.
weight loss with risedronate for bone health

Conditions: Bariatric Surgery Candidate; Bone Loss; Weight Loss

Summary: this is a pilot project to determine the feasibility of recruiting, enrolling, treating, and following 24 older sleeve gastrectomy patients into a randomized controlled trial (rct) examining the efficacy of bisphosphonate use versus placebo in the prevention of surgical weight loss associated loss of bone mass and quality.

this pilot study is a rct, involving 24 participants randomized to risedronate or placebo capsules for 24 weeks. all subjects planning a sleeve gastrectomy (sg) procedure will be approached during their pre-surgical evaluation for possible participation in the study. eligible participants will be referred onto the study coordinator to read/sign an irb-approved informed consent prior to enrollment. two in-person baseline assessment visits \[baseline visit 1 (bv1), baseline visit 2 (bv2)\] occurring 1-6 weeks prior to surgery, and two in-person follow up assessment visits \[follow up visit 1 (fv1) and follow up visit 2 (fv2)\] occurring ±2 weeks from their 23-week post-surgery date will be conducted, as well as monthly medication compliance reminders and adverse event reporting via phone. optional additional exploratory assessments include ct-derive bone health and blood-based biomarkers, as well as 12-month dxa, ct, and blood assessments. the wake forest wmc, under the direction of drs. ard and fernandez, will serve as a source of recruitment for potential study participants.

Eligibility criteria:
inclusion criteria * subjects planning a sleeve gastrectomy procedure * 40-79 yrs of age * willingness to provide informed consent * agreement to all study procedures and assessments exclusion criteria * age \<40 years * baseline weight \>450 pounds * chronic anti-reflux treatment * history of medical disorders known to affect bone metabolism * use of bone-active medications * known allergy to risedronate

Keywords: bone health
temporal characterization of extracellular vesicles during cellular therapy using car-t cells and during the occurrence of immune effector cell-associated neurotoxicity syndrome

Conditions: Immune Effector Cell Associated Neurotoxicity Syndrome

Summary: immune effector cell-associated neurotoxicity syndrome (icans) is a common and serious neurological complication associated with the use of car-t cells. the mechanisms involved are still poorly understood but studies suggest that inflammation during treatment leads to an increase in the permeability of the barrier between the brain and the blood vessels and the emission of extracellular vesicles (evs) circulating between the brain and the blood vessels. evs are biological particles that play an important role in cellular communication and the modulation of several physiological processes. the vesicans study aims to characterize the evs released before and during car-t cells treatment and upon the occurrence of icans, using flow cytometry, electron microscopy, nanoparticle tracking analysis associated with mri assessment of the barrier between the brain and blood. this study will ultimately contribute to facilitating the prevention and treatment of this toxicity which affects the prognosis of patients.


Eligibility criteria:
inclusion criteria: * patient aged over 18, * patient for whom car-t treatment is indicated, * patient affiliated to a social security system * patient who give his consent to participate in the study. exclusion criteria: * pregnant or breastfeeding woman, * patient unable to understand informed consent, * patient under legal protection.

Keywords: car-t cell icans evs
evaluation of prevalence and risk factors of persistent covid-19 in immunocompromised patients

Conditions: Persistent COVID-19; B Cell Malignancies

Summary: spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent sars-cov-2 infection within a population of hematology patients with humoral immunity deficiency.

spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent sars-cov-2 infection within a population of hematology patients with humoral immunity deficiency. the retrospective recruitment period will span from january, 1st, 2022 to the date of authorisation by hospital directorates following the ethics committees' approvals. this period has been established considering the prevalent diffusion of the omicron variant and its subvariants, which has led to significant changes in the clinical manifestations of covid-19. the prospective recruitment will be carried out over the 12 months immediately following the retrospective period. during the study period, screening for persisting sars-cov-2 infection and therapeutic management of all patients will be carried out by the attending physicians according to routine practice. this study is enclosed in the eu horizon 2020 project "connecting european cohorts to increase common and effective response to sars-cov-2 pandemic: orchestra" (grant agreement no. 101016167) and is located within task 4.6 "prevalence, risk factors and therapeutic management of persistent covid-19 in frail patients." it is expected to enroll approximately 1,000 patients (500 at the coordinating center).

Eligibility criteria:
inclusion criteria: * diagnosis of b cell malignancies or previous treatment with b cell targeting therapies. * diagnosis of proven sars-cov-2 infection confirmed by a pcr test (only the first infection during the study period will be considered, re-infection will be counted as a secondary endpoint). * provision of signed and dated informed consent. exclusion criteria: * none

Keywords: covid-19 persistent sars-cov-2 infection immunocompromised patients b cell malignancies b cell targeting therapies viral infections in the hematological patient
impact of switching to nnrti-based therapy on the quality of life of hiv-infected patients with virological suppression

Conditions: HIV Infections

Summary: observational study to evaluate therapeutic switch to a nnrti-based regimen on quality of life of hiv-positive patients


Eligibility criteria:
inclusion criteria: * nnrti-naive patients with positive hiv serology, treated with at least triple combination therapy, with a viral load \< 500 copies/ml, in whom a new treatment comprising an nnrti is initiated for a reason other than inefficacy of treatment will be included * patients must read and write french exclusion criteria: * patients in whom a new treatment is initiated because of treatment failure * new treatment does not comprise an nnrti
study of epratuzumab (hll2) in patients with waldenstrom's macroglobulinemia

Conditions: Waldenstrom Macroglobulinemia

Summary: the purpose of this study is to determine whether epratuzumab provides effective therapy in waldenström's macroglobulinemia (wm).

this multi-center, single-arm study of epratuzumab is in patients with waldenström's macroglobulinemia (wm) who failed chemotherapy. after baseline evaluations, patients receive epratuzumab infused over approximately 30-60 minutes at 360 mg/m2, administered once weekly for 4 consecutive weeks (days 1, 8, 15, 22). post-treatment evaluations occur on the day of the last infusion, then at 6 and 12 weeks. patients without progression of disease continue long-term follow up until disease progression or for at least 5 years, with evaluations every 3 months for 2 years, then semi-annually. otherwise, follow-up is only required until resolution of any treatment related abnormalities.

Eligibility criteria:
inclusion criteria: * documented diagnosis of waldenström's macroglobulinemia using criteria proposed at 2nd international workshop on wm, athens, greece, 2002. * measurable disease, defined as serum monoclonal igm protein ≥1000 mg/dl by electrophoresis. * lymphoplasmacytic infiltration of the bone marrow \>10% involvement. * failed at least one, but no more than 3, regimen(s) of prior therapy. (please consult with study site for full eligibility criteria)

Keywords: epratuzumab (hll2- anti-cd22 humanized antibody) waldenstrom's macroglobulinemia waldenstrom macroglobulinemia hematologic disease hematologic diseases paraproteinemias vascular hemostatic disorders lymphoproliferative disorders